Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia

Bibliography

• Juliusson G, Antunovic P, Derolf Å, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113(18):4179-87
   PubMed Web of Science ®Google Scholar
• Yanada M, Garcia-Manero G, Borthakur G, et al. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer 2007;110(12):2756-60
   PubMedGoogle Scholar
• Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol 2014;32(18):1919-26
   PubMed Web of Science ®Google Scholar
• Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989;7(8):1071-80
   PubMed Web of Science ®Google Scholar
• Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: A comprehensive review of the literature. Leuk Lymphoma 2002;43(9):1715-27
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23(9):1969-78
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Tomita K, Shibamori K, et al. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem 2004;47(8):2097-109
   PubMed Web of Science ®Google Scholar
• Hawtin RE, Stockett DE, Byl JA, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 2010;5(4):e10186
   PubMed Web of Science ®Google Scholar
• Hawtin RE, Stockett DE, Wong OK, et al. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget 2010;1(7):606-19
   PubMedGoogle Scholar
• Walsby EJ, Coles SJ, Knapper S, et al. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 2011;96(3):393-9
   PubMed Web of Science ®Google Scholar
• Evanchik MJ, Allen D, Yoburn JC, et al. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiaz olyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos 2009;37(3):594-601
   PubMed Web of Science ®Google Scholar
• Hoch U, Lynch J, Sato Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol 2009;64(1):53-65
   PubMed Web of Science ®Google Scholar
• Mjos KD, Cawthray JF, Jamieson G, et al. Iron(iii)-binding of the anticancer agents doxorubicin and vosaroxin. Dalton Trans 2015;44(5):2348-58
   PubMed Web of Science ®Google Scholar
• Freeman C, Keane N, Swords R, et al. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? Expert Opin Pharmacother 2013;14(10):1417-27
   PubMed Web of Science ®Google Scholar
• Lancet JE, Ravandi F, Ricklis RM, et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia 2011;25(12):1808-14
   PubMed Web of Science ®Google Scholar
• Scatena CD, Kumer JL, Arbitrario JP, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol 2010;66(5):881-8
   PubMed Web of Science ®Google Scholar
• Lancet JE, Roboz GJ, Cripe LD, et al. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica 2015;100(2):231-7
   PubMed Web of Science ®Google Scholar
• Ravandi F, Ritchie EK, Sayar SH, et al. Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: Results of a Phase III double-blind randomized controlled multinational study (VALOR). Blood 2014;124(21):Late Breaking abstract # 6.
   Google Scholar
• Stuart RK, Cripe LD, Maris MB, et al. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol 2015;168(6):796-805
   PubMed Web of Science ®Google Scholar
• Naval D, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosarxoin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS). Blood 2014;124(21):abstract # 385.
   Google Scholar
• Dennis M, Russell NH, Panoskaltsis N, et al. A randomised assessment of vosaroxin monotherapy and vosaroxin combined with low dose ara-C versus low dose ara-c in older patients with acute myeloid leukaemia. Blood 2014;124(21):ASH abstract # 3747.
   Google Scholar
• Weltermann A, Fonatsch C, Haas OA, et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2003;18(2):293-302
   Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109(6):1114-24
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28(4):562-9
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122:1384-94
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013;27(1):75-81
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30(21):2670-7
   PubMed Web of Science ®Google Scholar
• Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 2003;82(4):231-5
   PubMed Web of Science ®Google Scholar
• Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999;13(8):1214-20
   PubMed Web of Science ®Google Scholar
• Vogler WR, McCarley DL, Stagg M, et al. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A southeastern cancer study group trial. Leukemia 1994;8(11):1847-53
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thepot S, Berthon C, et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leukemia Res 2015;39(2):124-30
   PubMed Web of Science ®Google Scholar